Upgrade to SI Premium - Free Trial

UBS Reiterates Neutral Rating on Pfizer (PFE)

May 27, 2026 9:46 AM
UBS analyst Michael Yee reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).The analyst commented, "PFE's Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments